Chinese Antibody Society

T-cell engagers (TCEs) are a rapidly evolving novel group of treatments that have in common the concurrent engagement of a T-cell surface molecule and a tumoral cell antigen. We have observed many TCE licensing deals just in the past several months. Thus, it’s a good time now to bring your attention to our company’s official journal, Antibody Therapeutics which calls for papers regarding cell therapies and cell engagers against cancer. This special collection encourages the submission of original research and review articles covering a broad range of topics in the fields of cell therapy and cell engagers. This includes TILs, TCR-T, CAR-T, natural killer (NK) cells, and other immune cell-based therapies. We also invite contributions on all formats of cell engagers that redirect T cells, NK cells, macrophages, and other immune cells. The deadline for submitting manuscripts for this collection is 30 June 2025.  Antibody Therapeutics is the official journal of Chinese Antibody Society, and is an international peer-reviewed, open access journal published by Oxford University Press. Antibody Therapeutics is indexed by ESCI, PubMed and Scopus (2023 CiteScore: 8.7). You are welcome to visit the official website of the journal (see link below) and submit your therapeutic antibody related manuscripts to our journal by June 30, 2025 to enjoy 50% APC (Article Processing Charge/publication fee) discount. https://lnkd.in/gsTu_U2 #antibodies #antibody #antibodytherapeutics #mabs #mab #antibodydiscovery #biologics #celltherapy #celltherapies #cellengagers

We highly recommend this excellent review article regarding allosteric antibodies with the title of “Allosteric antibodies : a novel paradigm in drug discovery” The authors define an allosteric antibody as “an antibody that binds to the target on a site/epitope that does not overlap or sterically overlap with the ligand binding site and which subsequently has an impact on the structural dynamics of the target, ultimately modulating its binding and/or activity”. This review delves into the rapidly growing field of allosteric antibodies, highlighting recent therapeutic advancements and novel druggability avenues. The authors also explore the potential of these antibodies as innovative tools in drug discovery and discuss contemporary strategies for designing novel allosteric antibodies, leveraging stateof-the-art computational approaches. The authors of this paper are :  Léxane Fournier, Enrico Guarnera, Harald Kolmar, and Stefan Becker. Open access to this article at: https://lnkd.in/g6hyb-NW Chinese Antibody Society is an independent non-profit, non-government global professional organization with focus upon antibody-based therapeutics. Our society’s official journal, Antibody Therapeutics is an international peer-reviewed, open access journal published by Oxford University Press, and is indexed by ESCI, PubMed and Scopus (2023 CiteScore: 8.7). You are welcome to visit the official website of the journal (see link below) and submit your therapeutic antibody related manuscripts to our journal by June 30, 2025 to enjoy 50% APC (Article Processing Charge/publication fee) discount. . https://lnkd.in/gsTu_U2 #antibodies #antibody #antibodytherapeutics #antibodydiscovery #antibodydevelopment #mabs #mab #biologics

We’d like to feature this excellent review article published in Antibody Therapeutics with the title of "Next generation of multispecific antibody engineering”. The authors of this article from Gilead Sciences look at promising protein building blocks that can be used to assemble multispecifics, discuss advancements in computational protein design that have been used to overcome challenges, and what it will take to enable rapid and reliable multispecific design via machine learning. This paper was published in January 2024, and has received 14 citations and nearly 14,000 views/downloads. The corresponding author of this paper is Dr. Fernando Garces who is currently the CEO of BioGlyph. Open access to this paper at: https://lnkd.in/eXs2qsre Antibody Therapeutics is the official journal of Chinese Antibody Society, and is an international peer-reviewed, open access journal published by Oxford University Press. Antibody Therapeutics is indexed by ESCI, PubMed and Scopus (2023 CiteScore: 8.7). You are welcome to visit the official website of the journal (see link below) and submit your therapeutic antibody related manuscripts to our journal by June 30, 2025 to enjoy 50% APC (Article Processing Charge/publication fee) discount. https://lnkd.in/gsTu_U2 #antibodies #antibody #antibodytherapeutics #mabs #mab #antibodydiscovery #antibodydevelopment #biologics

BioArctic announced this week that it has entered into a global exclusive license agreement with Bristol Myers Squibb for BioArctic’s PyroGlutamate-amyloid-beta (PyroGlu-Aβ) antibody program, including BAN1503 and BAN2803, whereof the latter includes BioArctic’s BrainTransporter technology. As part of the agreement, BioArctic will receive a USD 100 million upfront payment and up to USD 1.25 billion in milestone payments. BioArctic is also entitled to tiered low double-digit royalties on global product sales. https://lnkd.in/dgKwm4S3 #antibody #antibodies #mAb #mAbs #biologic #biologics #BBB #neuroscience

This most recent Nature Communications paper looks interesting to us. This paper demonstrates that the combination of p95HER2.CAR T cells and HER2 x CD3 bispecific antibodies lead to a complete regression in three HER2-positive, patient-derived mouse xenografts tumor models (Note: p95HER2 is a tumor-specific antigen found in HER2-amplified solid tumors). This combination represents a promising strategy to redirect T cells against a subset of HER2-positive tumors. Chinese Antibody Society is an independent non-profit, non-government global professional organization with focus upon antibody-based therapeutics. Our society’s official journal, Antibody Therapeutics is an international peer-reviewed, open access journal published by Oxford University Press, and is indexed by ESCI, PubMed and Scopus (2023 CiteScore: 8.7). You are welcome to visit the official website of the journal (see link below) and submit your therapeutic antibody related manuscripts to our journal. https://lnkd.in/gsTu_U2 #antibody #antibodies #antibodydiscovery #antibodytherapeutics #celltherapy

A New “3-in-1” Antibody Shows Promise for Faster, Safer Cancer Therapy！ This new open access paper looks very interesting to us. It’s entitled “A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T Cell proliferation and anti-tumor immunity in mice”.  Researchers have developed a unique type of antibody that both targets and delivers a drug package via the antibody itself, while simultaneously activating the immune system (“3-in-1 design”) for personalized immunotherapy treatments. Researchers at Uppsala University and KTH Royal Institute of Technology have created a groundbreaking antibody that combines targeting, delivery, and immune activation to treat cancer, showing success in preclinical tests. Open access to this paper at: https://lnkd.in/gSsr_wny A news report regarding this article: https://lnkd.in/gaqPThes Chinese Antibody Society is an independent non-profit, non-government global professional organization with focus upon antibody-based therapeutics. Our society’s official journal, Antibody Therapeutics is an international peer-reviewed, open access journal published by Oxford University Press, and is indexed by ESCI, PubMed and Scopus (2023 CiteScore: 8.7). You are welcome to visit the official website of the journal (see link below) and submit your therapeutic antibody related manuscripts to our journal by June 30, 2025 to enjoy 50% APC (Article Processing Charge/publication fee) discount. . https://lnkd.in/gsTu_U2 #antibodies #antibody #antibodytherapeutics #antibodydiscovery #antibodydevelopment #mabs #mab #biologics

Candid Therapeutics, a new San Diego biotech bent on becoming a leader in the emerging T-cell engager space, has unwrapped three new research collaborations focusing on autoimmune diseases. Candid will partner with EpimAb Biotherapeutics, Inc. , Nona Biosciences and Ab Studio to beef up its pipeline of bispecific antibodies. https://lnkd.in/eU4ktbC6

Absolutely impressed by the 2024 mabTalk Symposium! A heartfelt thank you to the incredible speakers, attendees, sponsors, and last but not least, our dedicated volunteers. Your selfless efforts made this event an outstanding platform for scientific discussion and networking. Looking forward to seeing you all at the next event hosted by our society! #mab #mabs #antibody #antibodies #antibodyplus #bispecific #bsab #bsabs #bispecificantibody #bispecificantibodies #adc #adcs #antibodydrugconjugate #antibodydrugconjugates #antibodydiscovery #antibodydevelopment #biologics #symposium

We’d like to spotlight this mini review article published in Antibody Therapeutics in 2022 with the title of “The emergence of AntibodyPlus: the future trend of antibody-based therapeutics”. With more nontraditional antibody-based or antibody-containing therapeutics emerging from late-stage development into the market, the authors herein formally introduce the all-embracing concept of AntibodyPlus and discussed its scope, advantages and applications, setting up a foundation for further discussion in the field and to inspire more innovative strategies in developing antibody therapeutics. The authors are Yong Zhu, Shawn Shouye Wang (王守业）, Zhaohui Sunny Zhou, and Mitchell Ho （何苗壮）. Open access to this paper at: https://lnkd.in/gMksXW7E Antibody Therapeutics is the official journal of Chinese Antibody Society, and is an international peer-reviewed, open access journal published by Oxford University Press. Antibody Therapeutics is indexed by ESCI, PubMed and Scopus (2023 CiteScore: 8.7). You are welcome to visit the official website of the journal (see link below) and submit your therapeutic antibody related manuscripts to our journal by June 30, 2025 to enjoy 50% APC (Article Processing Charge/publication fee) discount. https://lnkd.in/gsTu_U2 #antibodies #antibody #antibodytherapeutics #mabs #mab #antibodydiscovery #antibodydevelopment #biologics

Congratulations to Candid Therapeutics, a San Diego-based biotechnology company and EpimAb Biotherapeutics, Inc. Biotherapeutics, a clinical-stage biopharmaceutical company specializing in the development of multi-specific antibodies. The two companies just announced a research collaboration to discover and develop novel T-cell Engager program candidates for various autoimmune indications. Under this agreement, EpimAb will receive an upfront payment along with milestone payments potentially exceeding $1 billion, assuming multiple candidates advance to commercialization. Candid has exclusive worldwide rights to develop and commercialize programs discovered under the collaboration. https://lnkd.in/e6EbTX87 Antibody Therapeutics is the official journal of Chinese Antibody Society, and is an international peer-reviewed, open access journal published by Oxford University Press. Antibody Therapeutics is indexed by ESCI, PubMed and Scopus (2023 CiteScore: 8.7). You are welcome to visit the official website of the journal (see link below) and submit your therapeutic antibody related manuscripts to our journal by June 30, 2025 to enjoy 50% APC (Article Processing Charge/publication fee) discount. https://lnkd.in/gsTu_U2 #BispecificAb #antibodies #antibody #bispecific #mabs #mab #antibodytherapeutics #antibodydiscovery #biologics #antibodydiscovery